2012-002814-38
ergab 2 Treffer. Klicken Sie auf den Titel um sich weitere Details anzeigen zu lassen.
Die Studienpraxis Urologie partizipiert in allen aktuellen, zentralen, klinischen Phase II, III und IV -Studien zur medikamentösen Behandlung des Prostatakarzinoms und darf auf eine Erfolgsgeschichte abgeschlossener Trials als einer der internationalen Top-Recruiter verweisen
PARP-Inhibitor Olaparib, open-label bei Vorliegen einer BRCA Mutation versus Abiraterone / Enzalutamid entsprechend ärztlicher Entscheidung, PROFOUND, Phase III
8th top recruiter in world, 1st in Germany
Top recruiter in Germany
Top recruiter in Germany
Top recruiter in Germany
2012-002814-38
Top recruiter in Germany
Top recruiter in Germany
Top recruiter in Germany
Top recruiter in Germany
Top recruiter in Germany
Abiraterone in Kombination mit neu begonnener LH-RH Therapie beim Hochrisikopatienten mit Prostatakarzinom, LATITUDE, Phase II, EudraCT Nr. 2012-002940-26
Top recruiter in Germany
Randomized, double-blind, comparative study of Abiraterone Acetata plus Prednisone plus androgen deprivation therapy (ADT) verus ADT alone in newly diagnosed subjects with high-risk, metastatic hormone-naive prostate cancer (mHNPC), LATITUDE, phase III, EudraCT: 2012-002940-26 33
Top recruiter in Germany
Cabozantinib versus Prednisone in metastatic hormonrefractory prostate cancer, COMET-1, XL194-307, phase III, EudraCT No 2012-001834-33
Top recruiter in Germany
Treatment with Degarelix versus Goserelin in hormone-naive prostate cancer patients, phase III, EudraCT No 2008-005276-27
Top recruiter in Germany
Open label study with enzalutamide in patients with hormone-refractory prostate cancer having progressed on abiraterone therapy, phase IV, EudraCT No 2 013-002271-17
2nd top recruiter in world, 1st in Germany
Randomized double-blind study with PROSTVAC-V/F +/- GM-CSF in men with asymptomatic or mildly symptomatic metastatic, castrate-resistant prostate cancer, phase III, EudraCT No 2 010-021196-85
2nd top recruiter in Germany
Randomized double-blind study with RNActive versus placebo in metastasized, chemonaive, hormone refractory prostate cancer patients, phase IIb, EudraCT No 2011-006314-14
Top recruiter in world
TAK-700 / Prednisone versus placebo in chemonaive metastatic hormone refractory prostate cancer patients, phase III, EudraCT No 2010-018661-35
Top recruiter in Germany
2nd top recruiter in Germany
Firstlinetherapy with Doce / Prednisone +/- OGX-011 in metastatic hormone refractory prostate cancer patients, phase III, EudraCT No 2010-021011-16
2nd top recruiter in world, 1st in Germany
3rd top recruiter in world, 1st in Germany
Adresse: http://www.studienurologie.de/referenzen/top-anzahl-betreuter-patienten/ Treffer-Übereinstimmung: 0,01
Prostatakarzinom:
2012-002814-38
Urothelkarzinom:
Adresse: http://www.studienurologie.de/klinische-studien/chronologie-unserer-studien/ Treffer-Übereinstimmung: 0,01